726 - Substandard and Fake Drugs
Public Health On Call
The Johns Hopkins Bloomberg School of Public Health
4.6 • 644 Ratings
🗓️ 28 February 2024
⏱️ 21 minutes
🧾️ Download transcript
Summary
Imagine going to the pharmacy to buy a needed medicine and then finding out you purchased a falsified product that was, at best, ineffective, but at worst contained something toxic or deadly? This is the unfortunate reality in many places worldwide. Dr. Murray Lumpkin, who leads global regulatory systems for the Bill & Melinda Gates Foundation, talks with Lindsay Smith Rogers about the substantial problem of substandard and falsified drugs, and what the world's watchdog systems are trying to do to counter them.
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Welcome to Public Health On Call, a podcast from the Johns Hopkins Bloomberg School of Public Health, |
| 0:05.9 | where we bring evidence, experience, and perspective to make sense of today's leading health challenges. |
| 0:16.3 | If you have questions or ideas for us, please send an email to public health question at jh.edu. |
| 0:23.8 | That's public health question at jh.edu for future podcast episodes. |
| 0:32.4 | This is Lindsay Smith Rogers. |
| 0:34.7 | Today, our topic is substandard and falsified drugs. Dr. Murray Lumpkin worked for the |
| 0:40.4 | FDA for 24 years and now leads global regulatory systems initiatives at the Bill and Melinda |
| 0:46.3 | Gates Foundation. We talk about what substandard and falsified drugs are, where they come from, |
| 0:52.6 | and the real harm they can cause, including death. |
| 0:56.0 | We also talk about why this market exists in the first place and what can be done to tamp down |
| 1:01.6 | on fake or substandard drugs globally. Let's listen. Dr. Murray Lumpkin, thank you so much for being |
| 1:08.0 | on public health on call. First, can you tell us a little bit about the work that you do? |
| 1:13.5 | Yeah, hi, and let me thank you for asking me to be with you today. |
| 1:17.6 | It's a great honor and pleasure. |
| 1:20.2 | Currently, and for the past 10 years, I have worked and am working at the Bill and Melinda Gates Foundation. I am the lead for what we call |
| 1:32.4 | our global regulatory systems initiatives, which means that it's work we do with partners around |
| 1:40.6 | the world to try to optimize the various regulatory systems through which global health |
| 1:47.7 | medical products have to go in order to be legally bought and used in the lower income |
| 1:55.5 | countries that we focus on. Prior to that, I was with the U.S. FDA for about 25 years. I'm a physician, |
| 2:04.6 | pediatric infectious disease, and tropical medicine doc by trade, but I've been in this |
| 2:11.1 | regulatory space for about the past 35 years. So today we're going to talk about substandard and counterfeit drugs. Let's start off, |
| 2:22.8 | what sort of falls under the umbrella of a substandard or a counterfeit drug? |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from The Johns Hopkins Bloomberg School of Public Health, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of The Johns Hopkins Bloomberg School of Public Health and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.